Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mianserin→

Mianserin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
24219-97-4
Molecular formula
C18H20N2
Molecular weight
264.4 g/mol
Drug class
Tetracyclic antidepressantnoradrenergic and specific serotonergic antidepressant (NaSSA-like pharmacology)
Mechanism of action
Antagonises presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, increasing noradrenergic and serotonergic neurotransmission. It also antagonises 5-HT2 and 5-HT3 receptors and has potent H1-histamine receptor antagonism that contributes to sedation.
Indications / reported uses
  • Treatment of depressive illness in adults in countries where mianserin is authorised; product availability and current indications are jurisdiction-specific

Sources: PubMed — Mianserin pharmacology and antidepressant action · NLM MeSH — Mianserin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mianserin Environmental Risk Assessment (ERA) (the Mianserin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.